Literature DB >> 19659548

Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing.

Armando Tripodi1, Veena Chantarangkul, Pier M Mannucci.   

Abstract

Acquired coagulation defects are characterized by a decrease of both pro- and anti-coagulants. Because of this, we hypothesise that global tests, such as the prothrombin and partial thromboplastin times (PT and APTT), might be unsuitable for their investigation. Indeed, these tests are not good predictors of bleeding in acquired coagulopathies as they are in the congenital ones. This article discusses the possible reasons for this, using cirrhosis and the neonatal period as epitomes of acquired coagulation defects. Both display normal thrombin generation in the presence of thrombomodulin, in spite of prolonged PT and APTT. We surmise that, because of their design, the PT and APTT are responsive to thrombin generated as a function of pro-coagulants, but much less to thrombin inhibited by the anti-coagulants, especially protein C, which is activated to a limited extent in the absence of thrombomodulin. In conclusion, the PT and APTT can tell us whether or not a patient is deficient in one or more pro-coagulants, but not whether this deficiency is counterbalanced by a parallel deficiency of anti-coagulants. Thrombin generation assays are more suitable than PT and APTT for use in acquired coagulation defects.

Entities:  

Mesh:

Year:  2009        PMID: 19659548     DOI: 10.1111/j.1365-2141.2009.07833.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.

Authors:  Armando Tripodi; Adriana Branchi; Veena Chantarangkul; Marigrazia Clerici; Giuliana Merati; Andrea Artoni; Pier Mannuccio Mannucci
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

Review 2.  Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

Authors:  Franco Scaldaferri; Stefano Lancellotti; Marco Pizzoferrato; Raimondo De Cristofaro
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

3.  Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy.

Authors:  Ross A Davenport; Maria Guerreiro; Daniel Frith; Claire Rourke; Sean Platton; Mitchell Cohen; Rupert Pearse; Chris Thiemermann; Karim Brohi
Journal:  Anesthesiology       Date:  2017-01       Impact factor: 7.892

4.  Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma.

Authors:  Armando Tripodi; Veena Chantarangkul; Massimo Primignani; Marigrazia Clerici; Alessandra Dell'era; Alessio Aghemo; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2011-02-05       Impact factor: 3.397

5.  Role of anticoagulant therapy in liver disease.

Authors:  Elisabeth P C Plompen; Jeoffrey N L Schouten; Harry L A Janssen
Journal:  Hepatol Int       Date:  2013-03-26       Impact factor: 6.047

6.  Body mass index reduction improves the baseline procoagulant imbalance of obese subjects.

Authors:  Armando Tripodi; Massimo Primignani; Sara Badiali; Fausto de Ruberto; Paola Granelli; Giulia Tosetti; Marigrazia Clerici; Lidia Padovan; Veena Chantarangkul; Erica Scalambrino; Flora Peyvandi
Journal:  J Thromb Thrombolysis       Date:  2019-07       Impact factor: 2.300

Review 7.  Venous thromboembolism in cirrhosis: a review of the literature.

Authors:  Michelle Buresi; Russell Hull; Carla S Coffin
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

8.  Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.

Authors:  Armando Tripodi; Concetta T Ammollo; Fabrizio Semeraro; Mario Colucci; Elena Malchiodi; Elisa Verrua; Emanuele Ferrante; Giorgio Arnaldi; Laura Trementino; Lidia Padovan; Veena Chantarangkul; Flora Peyvandi; Giovanna Mantovani
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

9.  Viral cirrhosis: an overview of haemostatic alterations and clinical consequences.

Authors:  Francesca Romana Ponziani; Valerio De Stefano; Antonio Gasbarrini
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-30       Impact factor: 2.576

10.  Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia.

Authors:  Jez Fabes; Susan J Brunskill; Nicola Curry; Carolyn Doree; Simon J Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2018-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.